OpenAlex 2.104 eser 26 yazar konusu
Çalışmalar
2.104 eser
-
YÖKSİS
SJR Q1
JCR Q1
OpenAlex üst %1
OpenAlex 100.0%
Özet henüz yok.
-
YÖKSİS
SJR Q1
JCR Q1
OpenAlex üst %1
OpenAlex 100.0%
BACKGROUND: Standard first-line therapy for metastatic, squamous non-small-cell lung cancer (NSCLC) is platinum-based chemotherapy or pembrolizumab (for patients with programmed death ligand 1 [PD-L1] expression on ≥50% of tumor cells). More recently, pembrolizumab plus chemotherapy was shown to significantly prolong…
-
YÖKSİS
SJR Q1
JCR Q1
OpenAlex üst %1
OpenAlex 100.0%
BACKGROUND: Standard first-line therapy for metastatic, squamous non-small-cell lung cancer (NSCLC) is platinum-based chemotherapy or pembrolizumab (for patients with programmed death ligand 1 [PD-L1] expression on ≥50% of tumor cells). More recently, pembrolizumab plus chemotherapy was shown to significantly prolong…
-
YÖKSİS
SJR Q1
JCR Q1
OpenAlex üst %1
OpenAlex 100.0%
BACKGROUND: Standard first-line therapy for metastatic, squamous non-small-cell lung cancer (NSCLC) is platinum-based chemotherapy or pembrolizumab (for patients with programmed death ligand 1 [PD-L1] expression on ≥50% of tumor cells). More recently, pembrolizumab plus chemotherapy was shown to significantly prolong…
-
European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications 2015YÖKSİS SJR Q1 JCR Q1 OpenAlex üst %1 OpenAlex 100.0%
The European Myeloma Network provides recommendations for the management of the most common complications of multiple myeloma. Whole body low-dose computed tomography is more sensitive than conventional radiography in depicting osteolytic disease and thus we recommend it as the novel standard for the detection of lyti…
-
OpenAlex üst %1
OpenAlex 99.9%
All ligands of the epidermal growth factor receptor (EGFR), which has important roles in development and disease, are released from the membrane by proteases. In several instances, ectodomain release is critical for activation of EGFR ligands, highlighting the importance of identifying EGFR ligand sheddases. Here, we…
-
YÖKSİS
SJR Q1
JCR Q1
OpenAlex üst %1
OpenAlex 99.7%
Özet henüz yok.
-
YÖKSİS
SJR Q1
JCR Q1
OpenAlex üst %1
OpenAlex 99.8%
Özet henüz yok.
-
YÖKSİS
SJR Q1
JCR Q1
OpenAlex üst %1
OpenAlex 99.8%
Özet henüz yok.
-
YÖKSİS
SJR Q1
JCR Q1
OpenAlex üst %1
OpenAlex 99.8%
Özet henüz yok.
-
Heterozygous STAT1 gain-of-function mutations underlie an unexpectedly broad clinical phenotype 2016YÖKSİS SJR Q1 JCR Q1 OpenAlex üst %1 OpenAlex 99.8%
Since their discovery in patients with autosomal dominant (AD) chronic mucocutaneous candidiasis (CMC) in 2011, heterozygous STAT1 gain-of-function (GOF) mutations have increasingly been identified worldwide. The clinical spectrum associated with them needed to be delineated. We enrolled 274 patients from 167 kindreds…
-
YÖKSİS
SJR Q1
JCR Q1
OpenAlex üst %1
OpenAlex 99.8%
Özet henüz yok.
Akademisyenler
26 akademisyen
- KEMAL YELEKÇİ 21 yazar konusu
- ERTAN ŞAHİN 16 yazar konusu
- HAKİM ÇELİK 13 yazar konusu
- HÜSEYİN KAYADİBİ 11 yazar konusu
- ABDULLAH TAŞKIN 10 yazar konusu
- SERENAY ELGÜN ÜLKAR 9 yazar konusu
- DERYA İLEM ÖZDEMİR 8 yazar konusu
- SUZAN TABUR 7 yazar konusu
- AYDIN AYTEKİN 6 yazar konusu
- AYFER YURT KILÇAR 6 yazar konusu
- ÇİĞDEM İÇHEDEF 6 yazar konusu
- MEHMET ÖZBİL 5 yazar konusu